The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISA 2024 | Exploring the next era of treating AL amyloidosis: role of birtamimab
Jack Khouri, MD, Cleveland Clinic, Cleveland, OH, shares insights into a satellite symposium which focused on the role of birtamimab in the treatment of light chain (AL) amyloidosis. This agent was explored in the VITAL trial (NCT02312206), in which a survival benefit was observed in patients with late-stage disease, and is now being investigated in the AFFIRM-AL trial (NCT04973137). This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Janssen
